Sustaining Innovation Analyst Day

IR call - Acquisition of Bioverativ Inc.

Sanofi will acquire Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders.
Sanofi hosted a conference call & webcast on the acquisition for the financial community.

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies